Targeting the interactions between lymphocytes and liver cancer stem cells in combination with immunotherapy is a promising therapeutic strategy

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, with a poor prognosis and high recurrence rate. Liver cancer stem cells (LCSCs), a small subset of HCC cells, have the capacity for self-renewal and the property of treatment resistance, suggesting that LCSCs are key factors in causing poor prognosis for HCC patients. In addition, LCSCs interact with immune cells to participate in the formation of an immunosuppressive microenvironment and escape the immune surveillance in HCC, especially lymphocytes. At present, immunotherapies for HCC are mainly based on reactivating the lymphocyte system, including immune checkpoint inhibitors, multifunctional antibodies, and adoptive cell therapy. Therefore, blocking the interactions between lymphocytes and LCSCs in combination with immunotherapy may be a promising therapeutic strategy. This review summarizes the interaction mechanisms of lymphocytes and LCSCs and the current exploration of combination therapy in HCC.

Keywords

Hepatocellular carcinoma / liver cancer stem cells / lymphocytes / immunotherapy / therapeutic resistance

References

[1] Villanueva A.Hepatocellular carcinoma.N Engl J Med2019;380:1450-62

[2] Islami F,Sung H.Annual report to the nation on the status of cancer, part 1: national cancer statistics.J Natl Cancer Inst2021;113:1648-69

[3] Ju MR.Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver.Chin Clin Oncol2021;10:5

[4] Roxburgh P.Systemic therapy of hepatocellular carcinoma: are we making progress?.Adv Ther2008;25:1089-104

[5] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2012;379:1245-55

[6] Tang J,Wang DF.Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.Theranostics2020;10:5384-97 PMCID:PMC7196302

[7] Clarke MF,Dirks PB.Cancer stem cells-perspectives on current status and future directions: AACR wrkshop on cancer stem cells.Cancer Res2006;66:9339-44

[8] Xiang Y,Pang BY,Liu YN.The progress and prospects of putative biomarkers for liver cancer stem cells in hepatocellular carcinoma.Stem Cells Int2016;2016:7614971 PMCID:PMC5005617

[9] Ruiu R,Rolih V.Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer’s source. Cancer Immunotherapy. Elsevier; 2019. p. 119-88.

[10] Lo Re O,Giallongo S.Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4⁺CD25⁺FoxP3⁺ regulatory T cells activation.Theranostics2020;10:910-24 PMCID:PMC6929991

[11] Park DJ,Kim JH.EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.J Immunother Cancer2020;8:e000301 PMCID:PMC7206970

[12] Cheung PF,Wong NC.Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.Cancer Immunol Res2014;2:1209-19

[13] Lee TK,Ma S.Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.Nat Rev Gastroenterol Hepatol2022;19:26-44

[14] Hao X,Zhang Y.Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges.Front Cell Dev Biol2021;9:775462 PMCID:PMC8633569

[15] Sperandio RC,Miyamura BV.Hepatocellular carcinoma immunotherapy.Annu Rev Med2022;73:267-78

[16] Kreso A.Evolution of the cancer stem cell model.Cell Stem Cell2014;14:275-91

[17] Farhood B,Mortezaee K.CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: a review.J Cell Physiol2019;234:8509-21

[18] Bian J,Long J et al.T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy..Am J Cancer Res2020;10:4585-606 PMCID:PMC7783774

[19] Bálint Š,Fischer R.Supramolecular attack particles are autonomous killing entities released from cytotoxic T cells.Science2020;368:897-901 PMCID:PMC7116847

[20] Logtenberg MEW,Schumacher TN.The CD47-SIRPα immune checkpoint.Immunity2020;52:742-52 PMCID:PMC7340539

[21] Chiu DK,Cheu JW.Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-Cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice.Gastroenterology2020;159:609-23

[22] Jansen CS,Master VA.An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.Nature2019;576:465-70 PMCID:PMC7108171

[23] Zheng C,Yoo JK.Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing.Cell2017;169:1342-1356.e16

[24] Yang Y,Liu W.Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma.Clin Transl Med2020;10:e133 PMCID:PMC7418813

[25] Wang X,Shen H.TOX promotes the exhaustion of antitumor CD8⁺ T cells by preventing PD1 degradation in hepatocellular carcinoma.J Hepatol2019;71:731-41

[26] Barsch M,Schlaak AE.T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.J Hepatol2022;77:397-409

[27] McLane LM,Wherry EJ.CD8 T cell exhaustion during chronic viral infection and cancer.Annu Rev Immunol2019;37:457-95

[28] Zhou G,Boor PPC.Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T Cells in hepatocellular carcinomas.Gastroenterology2017;153:1107-1119.e10

[29] Wu Q,Yin S.Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer.Hepatology2019;70:198-214 PMCID:PMC6618281

[30] Tao H,Wang Y.Icaritin induces anti-tumor immune responses in hepatocellular carcinoma by inhibiting splenic myeloid-derived suppressor cell generation.Front Immunol2021;12:609295 PMCID:PMC7952329

[31] Morrison BJ,Morris JC.Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.BMC Cancer2018;18:469 PMCID:PMC5918869

[32] Guo X,Yan H.Single tumor-initiating cells evade immune clearance by recruiting type II macrophages.Genes Dev2017;31:247-59 PMCID:PMC5358722

[33] Gupta HB,Yuan B.Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.Signal Transduct Target Ther2016;1:16030- PMCID:PMC5547561

[34] Nishida N,Morita M.Association between genetic and immunological background of hepatocellular carcinoma and expression of programmed cell death-1.Liver Cancer2020;9:426-39 PMCID:PMC7506256

[35] Kaufhold S,Bonavida B.Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication.J Exp Clin Cancer Res2016;35:84 PMCID:PMC4881184

[36] Zhong F,Sun S.Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells.Oncol Rep2017;37:3061-7

[37] Chan LC,Xia W.IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.J Clin Invest2019;129:3324-38 PMCID:PMC6668668

[38] Huang CY,Luo GY.Relationship between PD-L1 expression and CD8⁺ T-cell immune responses in hepatocellular carcinoma.J Immunother2017;40:323-33

[39] Pan K,Wang H.Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate.Int J Biol Sci2010;6:639-48 PMCID:PMC2962266

[40] Shibolet O,Zlotogarov L.NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.Int J Cancer2003;106:236-43

[41] Yamashita T,Budhu A.EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.Gastroenterology2009;136:1012-24 PMCID:PMC2828822

[42] Ruiz de Galarreta M,Molina-Sánchez P.β-catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma.Cancer Discov2019;9:1124-41 PMCID:PMC6677618

[43] Pardee AD,Butterfield LH.Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.The Journal of Immunology2014;193:5723-32 PMCID:PMC4239186

[44] Pan QZ,Wang QJ.Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.Stem Cells2015;33:354-66

[45] Chen X,Huang Z.CD4⁺CD25⁺ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity.Immunology Letters2012;148:83-9

[46] Kryczek I,Wang G.FOXP3 Defines regulatory T cells in human tumor and autoimmune disease.Cancer Research2009;69:3995-4000

[47] Cabrera R,Eksioglu EA.Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.Scand J Immunol2010;72:293-301 PMCID:PMC2951624

[48] Ormandy LA,Wedemeyer H,Greten TF.Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.Cancer Res2005;65:2457-64

[49] Santoiemma PP.Tumor infiltrating lymphocytes in ovarian cancer.Cancer Biol Ther2015;16:807-20 PMCID:PMC4622931

[50] Pedroza-Gonzalez A,Ijzermans JN.Activated tumor-infiltrating CD4⁺ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.Hepatology2013;57:183-94

[51] Fu J,Liu Z.Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.Gastroenterology2007;132:2328-39

[52] Jiang R,Chen Y.The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion.Nat Commun2017;8:15129 PMCID:PMC5529670

[53] Suthen S,Nguyen PHD.Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC.Hepatology2022;76:1329-44

[54] Wang Z,Li W.GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.J Immunother Cancer2021;9:e002787 PMCID:PMC8422483

[55] Watson MJ,Mullett SJ.Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.Nature2021;591:645-51 PMCID:PMC7990682

[56] Zhou Y,Wu J.Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.BMC Cancer2016;16:506 PMCID:PMC4955266

[57] Cao W,Liu J.LGR5 marks targetable tumor-initiating cells in mouse liver cancer.Nat Commun2020;11:1961 PMCID:PMC7181628

[58] Ko CJ,Wu MY.Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma.Int J Environ Res Public Health2019;16:1836 PMCID:PMC6572154

[59] Liu XS,Mei Y.Regulatory T cells promote overexpression of Lgr5 on gastric cancer cells via TGF-beta1 and confer poor prognosis in gastric cancer.Front Immunol2019;10:1741 PMCID:PMC6682668

[60] Mima K,Ishimoto T.CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.Cancer Res2012;72:3414-23

[61] Yang P,Feng Y.TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma.Cancer Cell2012;22:291-303 PMCID:PMC3443566

[62] Sun C,Zhang C.NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.Cell Mol Immunol2015;12:292-302 PMCID:PMC4654321

[63] Liu P,Zhang H.Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell-based immunotherapy.J Immunol Res2018;2018:1206737 PMCID:PMC6142725

[64] Jinushi M,Tatsumi T.Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.J Hepatol2005;43:1013-20

[65] Cadoux M,Pham S.Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.J Hepatol2021;74:1386-97

[66] Rong XX,Lin XL.Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition.Oncoimmunology2016;5:e1086060 PMCID:PMC4839362

[67] Cheung PF,Wong NC.Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells.PLoS One2011;6:e28246 PMCID:PMC3241621

[68] Cheung PF,Ng LW.Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin-epithelin precursor.Oncoimmunology2015;4:e1016706 PMCID:PMC4485783

[69] Zhao H,Han Q.Homeobox containing 1 inhibits liver cancer progression by promoting autophagy as well as inhibiting stemness and immune escape.Oncol Rep2018;40:1657-65

[70] Weng J,Liu K.CD44 3'-Untranslated region functions as a competing endogenous RNA to enhance NK sensitivity of liver cancer stem cell by regulating ULBP2 expression.Int J Biol Sci2019;15:1664-75 PMCID:PMC6643214

[71] Sautès-Fridman C,Giraldo NA.Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention.Front Immunol2016;7:407 PMCID:PMC5046074

[72] Schumacher TN.Tertiary lymphoid structures in cancer.Science2022;375:eabf9419

[73] Fridman WH,Sautès-Fridman C.The immune contexture in cancer prognosis and treatment.Nat Rev Clin Oncol2017;14:717-34

[74] Finkin S,Stein I.Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.Nat Immunol2015;16:1235-44 PMCID:PMC4653079

[75] Calderaro J,Becht E.Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.J Hepatol2019;70:58-65

[76] Wu R,Qiu X.Comprehensive analysis of spatial architecture in primary liver cancer.Sci Adv2021;7:eabg3750 PMCID:PMC8683021

[77] Li L,Qin J.Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.Gastroenterology2014;146:1108-18 PMCID:PMC3982149

[78] Chen H,Sun W.Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells.Cancer Letters2013;336:204-12

[79] Chetty C,Da Costa Dias B.Anti-LRP/LR specific antibody IgG1-iS18 impedes adhesion and invasion of liver cancer cells.PLoS One2014;9:e96268 PMCID:PMC4010454

[80] Zhao W,Han H.1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit.Cancer Cell2013;23:541-56

[81] Tong M,Luk ST.ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma.Stem Cell Reports2015;5:45-59 PMCID:PMC4618447

[82] Tong M,Zhou L.Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.J Hepatol2018;69:826-39

[83] Suda T,Sunagozaka H.Dickkopf-1 promotes angiogenesis and is a biomarker for hepatic stem cell-like hepatocellular carcinoma.Int J Mol Sci2022;23:2801 PMCID:PMC8911428

[84] Chao MP,Majeti R.The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.Curr Opin Immunol2012;24:225-32 PMCID:PMC3319521

[85] Lee TK,Lu P.Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma.Hepatology2014;60:179-91

[86] Xiao Z,Banan B.Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.Cancer Lett2015;360:302-9 PMCID:PMC4886734

[87] Lo J,So FT.Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.Liver Int2016;36:737-45

[88] Lo J,Ching RH.Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.Hepatology2015;62:534-45

[89] Du K,Liu J.A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.Mol Ther2021;29:1572-84 PMCID:PMC8058486

[90] Soto-Pantoja DR,Ghosh A.CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.Cancer Res2014;74:6771-83 PMCID:PMC4253868

[91] Murali M,Nair B.Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.Clin Transl Oncol2022;24:407-31

[92] He H,Zhang J.A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging.Immunobiology2015;220:1328-36

[93] Ma Z,Sun F.Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.J Cancer Res Clin Oncol2017;143:1929-40

[94] Sun F,Luo X.Anti-CD24 Antibody-nitric oxide conjugate selectively and potently suppresses hepatic carcinoma.Cancer Research2019;79:3395-405

[95] Wang L,Liu Z.CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma.Biomaterials2012;33:5107-14

[96] Lee J,Kim H.Targeted multimodal nano-reporters for pre-procedural MRI and intra-operative image-guidance.Biomaterials2016;109:69-77 PMCID:PMC5055467

[97] Yang R,Miao QF.Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes.Oncotarget2016;7:35894-916 PMCID:PMC5094971

[98] An Y,Wang X.Facile Assembly of thermosensitive liposomes for active targeting imaging and synergetic chemo-/magnetic hyperthermia therapy.Front Bioeng Biotechnol2021;9:691091 PMCID:PMC8371754

[99] Han Y,Jia G.Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma.Nanoscale2018;10:6511-23

[100] Vivier E,Moretta A.Innate or adaptive immunity?.Science2011;331:44-9

[101] Ames E,Grossenbacher SK.NK Cells preferentially target tumor cells with a cancer stem cell phenotype.J Immunol2015;195:4010-9 PMCID:PMC4781667

[102] Han Y,Zhang X.CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.J Cancer Res Clin Oncol2019;145:1179-90

[103] Yu M.Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.Front Med2017;11:509-21

[104] Chang YH,Shimasaki N,Kono K.A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.Cancer Res2013;73:1777-86

[105] Kamiya T,Campana D.Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma.Cancer Immunol Res2016;4:574-81

[106] Lu SJ.CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.Stem Cells Transl Med2021;10 Suppl 2:S10-7 PMCID:PMC8560199

[107] Wrona E,Potemski P.CAR-NK cells in the treatment of solid tumors.Int J Mol Sci2021;22:5899

[108] Calderaro J,Amaddeo G.Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features.Hepatology2016;64:2038-46

[109] Hsu JM,Hsu YH.STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.Nat Commun2018;9:1908 PMCID:PMC5954021

[110] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[111] Finn RS,Merle P.for the KEYNOTE-240 InvestigatorsResults of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).JCO2019;37:4004-4004

[112] Yau T,Finn R.CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).Ann Oncol2019;30:v874-5

[113] Nishida N.Immune phenotype and immune checkpoint inhibitors for the treatment of human hepatocellular carcinoma.Cancers (Basel)2020;12:1274 PMCID:PMC7281618

[114] Finn RS,Ikeda M.IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).JCO2021;39:267-267

[115] Zhu AX,Ikeda M.A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).JCO2020;38:4519-4519

[116] Ren Z,Bai Y.ORIENT-32 study groupSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021;22:977-90

[117] Xu J,Gu S.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, Phase II trial.Clin Cancer Res2021;27:1003-11

[118] Zhang Y,Shen J.Update on overall survival (OS) of RESCUE: an open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).JCO2021;39:4076-4076

[119] Parsa AT,Panner A.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.Nat Med2007;13:84-8

[120] Chen D,Cheng Q.Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.J Clin Pathol2019;72:588-96

[121] Zhou H,Kong L.B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.Oncogene2019;38:3371-86 PMCID:PMC6756013

[122] Maude SL,Buechner J.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med2018;378:439-48 PMCID:PMC5996391

[123] Neelapu SS,Bartlett NL.Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma.N Engl J Med2017;377:2531-44

[124] Hegde PS.Top 10 challenges in cancer immunotherapy.Immunity2020;52:17-35

[125] Wang H,Ju Y.Minicircle DNA-mediated CAR T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo.Onco Targets Ther2020;13:3703-16 PMCID:PMC7210041

[126] Sun B,Dai H.Eradication Of Hepatocellular Carcinoma by NKG2D-Based CAR-T cells.Cancer Immunol Res2019;7:1813-23

[127] Wang Y,Wu Z.CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.Oncoimmunology2018;7:e1440169 PMCID:PMC5993480

[128] Adusumilli PS,Rivière I.A Phase I trial of regional mesothelin-targeted cAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab.Cancer Discov2021;11:2748-63 PMCID:PMC8563385

[129] Davies JS,Zhang L.Non-synergy of PD-1 blockade with T-cell therapy in solid tumors.J Immunother Cancer2022;10:e004906 PMCID:PMC9260838

[130] Zhai B,Gao H.A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3⁺ hepatocellular carcinoma (r/r GPC3⁺ HCC).JCO2017;35:3049-3049

[131] Batra SA,Guo L.Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma.Cancer Immunol Res2020;8:309-20

[132] Pang N,Qin L.IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.J Hematol Oncol2021;14:118 PMCID:PMC8323212

[133] Adachi K,Nagai T,Sakoda Y.IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.Nat Biotechnol2018;36:346-51

[134] Liang Z,Ji Z.The binding of LDN193189 to CD133 C-terminus suppresses the tumorigenesis and immune escape of liver tumor-initiating cells.Cancer Lett2021;513:90-100

[135] Yu L,Huang N.A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.Cancer Biol Ther2020;21:597-603 PMCID:PMC7515540

[136] Zhang P,Gao H.An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.Cancer Immunol Immunother2014;63:121-32

[137] Burges A,Kümper C.Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.Clin Cancer Res2007;13:3899-905

[138] Heiss MM,Koralewski P.The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.Int J Cancer2010;127:2209-21 PMCID:PMC2958458

[139] Wimberger P,Gonschior AK.Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.Ann Oncol2012;23:1979-85 PMCID:PMC3403730

[140] Wierecky J,Brossart P.Dendritic cell-based cancer immunotherapy targeting MUC-1.Cancer Immunol Immunother2006;55:63-7

[141] Sun JC,Chen MS.Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.Cancer Biol Ther2010;10:368-75

[142] Choi YJ,Park YS,Yang KM.EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells.PLoS One2018;13:e0190638 PMCID:PMC5752035

[143] Pang YB,Cui BY.A potential antitumor effect of dendritic cells fused with cancer stem cells in hepatocellular carcinoma.Stem Cells Int2019;2019:5680327 PMCID:PMC6466848

[144] Yang Y,Lin Z.Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells.Cell Mol Immunol2014;11:184-96 PMCID:PMC4003383

[145] Héninger E,Lang JM.Augmenting antitumor immune responses with epigenetic modifying agents.Front Immunol2015;6:29 PMCID:PMC4316783

[146] Bai X,Yokota Y.Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.J Exp Clin Cancer Res2022;41:132 PMCID:PMC8991500

[147] Woller N,Fleischmann-Mundt b.viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses.Mol Ther2015;23:1630-40 PMCID:PMC4817928

[148] Shigeta K,Hato T.Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma.Hepatology2020;71:1247-61 PMCID:PMC7000304